Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03173742
Other study ID # MS842-101
Secondary ID 2015-005690-20
Status Completed
Phase Phase 1
First received May 17, 2017
Last updated May 30, 2017
Start date March 2016
Est. completion date January 2017

Study information

Verified date May 2017
Source Chemo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of the bioavailability and safety of one oral preparation containing fixed dose 18 mg ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) or two oral preparations containing fixed dose 18 mg ivermectin (IVM 36 MG TABLETS, LICONSA S.A., Spain) vs. reference dosing (weight based) of reference drug containing 6 mg ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) in fasting conditions. A monocentric, open, randomized, single dose, three-period crossover trial in healthy volunteers.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date January 2017
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Caucasian subjects of either gender (male or female) with an age between 18 and 45 years (both inclusive).

2. Medical history and physical examination with no relevant abnormal findings.

3. No evidence of significant disease (organic or psychiatric) based on medical history, physical examination and complementary tests.

4. Laboratory tests (complete hematology, clinical chemistry and urinalysis).

5. Vital signs (systolic and diastolic blood pressure, heart rate and temperature) and electrocardiogram (ECG) record within normal range at screening.

6. Participating female volunteers must use a reliable contraception method not containing hormones. List of accepted contraception method includes barrier methods (i.e. female/male condoms, diaphragms, spermicides), voluntary sterilization (female tubal occlusion) or non-medicated intrauterine devices (IUD) (i.e. inert or copper-releasing). Abstention is not considered a reliable contraception method.

7. For female volunteers only: they must declare that they did not intend to become pregnant in the last month prior to screening and they do not intend to become pregnant during one month following the last study drug administration.

8. Voluntary participation in the study, with written informed consent from the volunteer.

9. The subject agrees to abstain from beverages or food containing methylxanthines (coffee, tea, cola, energy drinks, chocolate etc.), St John's Wort, vitamins, herbal remedies and chewing-gum for 48 hours prior to study drug administration and during each study period.

10. The subject agrees to abstain from beverages or food containing grapefruit for 14 days prior to the first study drug administration and during the study (until last sample from the last period).

Exclusion Criteria:

1. Background of allergy, idiosyncrasy or hypersensitivity to the study drugs or its excipients.

2. Heavy consumer of stimulating drinks (>5 cups of coffee, tea, chocolate or cola drinks per day).

3. Background of alcoholism or drug dependence in the last one year or daily consumption of alcohol > 40 gr/day for men or > 24 gr/day for women.

4. Use of any medication within 15 days prior to taking the study treatment, including over-the-counter medications and medicinal plants (except for the use of paracetamol in short-term symptomatic treatments).

5. Positive serology for hepatitis B, C or HIV.

6. Background or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological or neurological disease or other chronic diseases.

7. Smokers or ex-smokers that gave up smoking less than 1 year prior to the study (day 1 of period I)

8. Pregnancy or lactation status for female subjects.

9. Participation in another clinical trial during the 3 months before starting the current trial.

10. Donate blood in the 8 weeks prior to starting the study.

11. Undergone major surgery during the previous 6 months.

12. Clinically significant abnormal ECG with clinical significance in accordance with the CIM's clinical criterion

13. Restrictive vegetarian diet

14. Positive results to the breath alcohol test at screening or at Day -1

15. Positive results to the drug abuse checks (urine test for: amphetamines, cannabinoids, opiates, benzodiazepines and cocaine) at screening or at admission on Day -1

16. Epidemiological risk of being infected by Loa loa or other filariases, defined as those who have lived or have travelled to any of the following countries: Angola, Cameroon, Central Africa Republic, Chad, Congo, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
T1, T2, T3
T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight. T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
T1,T3,T2
T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight. T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
T2,T1,T3
T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight. T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
T2,T3,T1
T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight. T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
T3,T1,T2
T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight. T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
T3,T2,T1
T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight. T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Chemo

Outcome

Type Measure Description Time frame Safety issue
Primary Primary endpoint evaluated will be the PK parameters that define bioavailability in extent Ln [AUC0t] For group 3 up to day 7
Primary Primary endpoint evaluated will be the PK parameters that define bioavailability in extent in rate: Ln [Cmax] for each treatment in healthy volunteers with high weight (Group 3), calculated by means of a non-compartmental analysis. For group 3 up to day 7
Secondary Relative bioavailability for each treatment and for groups 1 and 2 will be evaluated with the PK parameters that define bioavailability in extent Ln [AUC0t] for group 1 and 2 up to day 7
Secondary Relative bioavailability for each treatment and for groups 1 and 2 will be evaluated with the PK parameters that define bioavailability in extent in rate: Ln [Cmax] for group 1 and 2 up to day 7
Secondary AUC0t (for non-compartmental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary AUC08 (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary %AUC extra (residual area) (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary tmax (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary tlag (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary Cl/F (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary V/F (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary t1/2 (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary Ke (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary MRT (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary Cmax (for non-compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary tlag (for compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary ka (for compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis D7
Secondary Cl/F(for compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary V/F (for compartimental analysis) PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis up to day 7
Secondary vital signs To asses safety and tolerability of the treatments up to week 6
Secondary laboratory analysis To asses safety and tolerability of the treatments up to week 6
Secondary Incidence of adverse events. To asses safety and tolerability of the treatments up to week 6
Secondary ECG To asses safety and tolerability of the treatments up to week 6
See also
  Status Clinical Trial Phase
Completed NCT04041453 - Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients Phase 2
Active, not recruiting NCT03014167 - Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Phase 3
Completed NCT02385058 - Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Phase 4
Withdrawn NCT02636803 - Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults Phase 2
Completed NCT02725255 - Design and Clinical Evaluation of a School Meal With Deworming Properties Phase 2/Phase 3
Active, not recruiting NCT04227834 - Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education N/A
Completed NCT02397772 - Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya Phase 4
Completed NCT00130910 - Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation N/A
Completed NCT00004996 - Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections
Recruiting NCT00001230 - Host Response to Infection and Treatment in Filarial Diseases
Completed NCT04041427 - Urine Albendazole Levels for Coverage Assessment N/A
Completed NCT02396407 - Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health N/A
Terminated NCT01271049 - An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths N/A
Terminated NCT00817713 - Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa? N/A
Completed NCT02362932 - The Effect of an Urban Sanitation Intervention on Child Health N/A
Completed NCT02420574 - Assessment of Drug Efficacy of Local Albendazole N/A
Completed NCT00507221 - Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression N/A
Completed NCT00469495 - Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis N/A
Recruiting NCT01459146 - Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Phase 4
Recruiting NCT01308268 - Management of Soil-transmitted Helminthiasis and Strongyloidiasis N/A